-
2024-516380-81-00
4
2025-02-28
Treatment of IgAN
-
2024-515661-34-00
6
2025-02-27
Transthyretin cardiac amyloidosis
-
2024-514333-37-00
4
2025-02-25
Advanced Metastatic Ocular/Uveal Melanoma
-
2023-507227-36-00
5
2025-02-21
SARS-CoV-2 (COVID-19) infection
-
2025-520777-39-00
6
2025-01-29
Complicated acute appendicitis
-
2023-508234-34-00
4
2025-01-27
Crohn's disease
-
2023-507201-34-00
6
2025-01-23
Atrial fibrillation
-
2024-514656-32-00
4
2025-01-23
Suspected or confirmed Gram negative infections
-
2024-513420-41-00
10
2025-01-09
prematurity in neonates
-
2024-512798-29-00
5
2025-01-07
Male and female patients aged ≥ 18 to ≤ 85 years with a total pancreat
-
2023-509717-36-00
5
2024-12-16
AF patients who have undergone successful PCI
-
2023-510150-17-00
4
2024-12-11
Active, refractory systemic lupus erythematosus (SLE), and active, re
-
2023-510380-34-00
4
2024-12-10
Diffuse cutaneous systemic sclerosis (dcSSc)
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2024-514177-21-00
4
2024-12-02
Solid tumours
-
2023-508191-11-00
5
2024-11-28
Systemic lupus erythematosus (SLE)
-
2024-513009-30-00
4
2024-11-21
Moderate to Severe Crohn’s Disease
-
2024-514917-36-00
5
2024-11-21
Patients with High Risk Neuroblastoma
-
2024-511465-11-00
5
2024-11-20
Spontaneous lobar ICH
-
2024-516600-42-00
6
2024-11-18
RSV-infection
-
2024-512338-13-00
3
2024-11-11
Metastatic Castration-Resistant Prostate Cancer
-
2023-509912-27-00
5
2024-11-07
Metabolic Dysfunction-Associated Steatotic Liver Disease(MASH) / Nonal
-
2023-510219-20-00
11
2024-11-04
Glycogen storage disease type Ia (GSDIa)
-
2024-514354-67-00
5
2024-11-01
Systemic lupus erythematosus